natgillin/translations-raw huggingface dataset:
There is a linear relationship between dose and both Cmax and AUC.
Med odmerkom ter Cmax in AUC obstaja linearna povezanost.
There is a linear relationship between the dose administered and plasma concentration observed in the therapeutic dose range in dogs.
Med vnesenim odmerkom in koncentracijo v plazmi je pri terapevtskem razponu odmerkov linearno razmerje.
There is a linear relationship between the dose administered and plasma concentration observed in the therapeutic dose range in dogs.
Pri terapevtskem razponu odmerkov je med vnesenim odmerkom meloksikama in koncentracijo v plazmi linearno razmerje.
There is a lower weight-adjusted clearance in obese subjects with subcutaneous dosing.
Pri debelih osebah je telesni masi prilagojen očistek po subkutani uporabi manjši.
There is a need to check the patient’s peripheral lymphocyte count (CBC) prior to initiation and to monitor during treatment with GILENYA.
Pred začetkom zdravljenja in med zdravljenjem z zdravilom GILENYA je treba bolniku določati število limfocitov v periferni krvi.
There is a need to monitor liver function tests prior to initiation of treatment with Esbriet and at regular intervals thereafter.
Pred začetkom zdravljenja z zdravilom Esbriet je treba preveriti delovanje jeter in ga nato redno spremljati.
There is a particularly high risk of becoming pregnant if you miss white active tablets close to the yellow placebo tablet interval.
Če pozabite vzeti bele aktivne tablete blizu časa jemanja rumenih placebo tablet, je možnost zanositve še posebej velika.
There is a possibility that new antibodies can form in your body when this medicine is used.
Obstaja verjetnost, da bodo po uporabi tega zdravila v telesu nastala nova protitelesa.
There is a possibility that vaccinated dogs facing a challenge with other babesia's may develop disease and require treatment.
Pri cepljenih psih, ki se okužijo z drugimi babezijami, se bolezen lahko razvije in jih je treba zdraviti.
There is a possible association between acetylsalicylic acid (ASA) and Reye’s Syndrome when products containing ASA are given to children or adolescents with a viral infection.
Obstaja možna povezava med acetilsalicilno kislino (ASA) in Reyevim sindromom, če otroci ali mladostniki dobijo zdravila z ASA pri virusni okužbi.
There is a potential for additive effects resulting in hypotension and/or marked bradycardia when ophthalmic beta blockers solution is administered concomitantly with oral calcium channel blockers, beta-adrenergic blocking agents, antiarrhythmics (including amiodarone), digitalis glycosides, parasympathomimetics, guanethidine.
Obstaja možnost za aditivne učinke, ki povzročijo hipotenzijo in/ali izrazito bradikardijo pri sočasni uporabi očesne raztopine zaviralcev adrenergičnih receptorjev beta s peroralnimi zaviralci kalcijevih kanalov, zaviralci adrenergičnih receptorjev beta, antiaritmiki (vključno z amiodaronom), glikozidi digitalisa, parasimpatikomimetiki ali gvanetidinom.
There is a potential for additive effects resulting in hypotension, and/or marked bradycardia when ophthalmic beta-blocker solution is administered concomitantly with oral calcium channel blockers, guanethidine, beta-adrenergic blocking agents, parasympathomimetics, anti-arrhythmics (including amiodarone) and digitalis glycosides.
Obstaja možnost aditivnih učinkov, ki lahko privedejo do hipotenzije in/ali znatne bradikardije, kadar se očesna raztopina antagonistov adrenergičnih receptorjev beta uporablja skupaj s peroralnimi zaviralci kalcijevih kanalov, gvanetidinom, antagonisti andrenergičnih receptorjev beta, parasimpatomimetiki, antiaritmiki (vključno z amiodaronom) in glikozidi digitalisa.
There is a potential for additive effects resulting in hypotension, and/or marked bradycardia when ophthalmic beta-blockers solution is administered concomitantly with oral calcium channel blockers, guanethidine, beta-adrenergic blocking agents, parasympathomimetics, anti-arrhythmics (including amiodarone) and digitalis glycosides.
Obstaja možnost aditivnih učinkov, ki lahko privedejo do hipotenzije in/ali znatne bradikardije, kadar se očesna raztopina antagonistov adrenergičnih receptorjev beta uporablja skupaj s peroralnimi zaviralci kalcijevih kanalov, gvanetidinom, antagonisti andrenergičnih receptorjev beta, parasimpatomimetiki, antiaritmiki (vključno z amiodaronom) in glikozidi digitalisa.
There is a potential for aliskiren overexposure in children with an immature MDR1 (P-gp) system (see “Transporters” above and sections 4.2, 4.4 and 5.3).
Pri otrocih z nezrelim sistemom MDR1 (P-gp) lahko pride do prevelike izpostavljenosti aliskirenu (glejte odstavek pod naslovom "Prenašalci" zgoraj in poglavja 4.2, 4.4 in 5.3).
There is a potential for aliskiren overexposure in children with an immature MDR1 (P-gp) system (see “Transporters” above and sections 4.2, 4.4 and 5.3).
Pri otrocih z nezrelim sistemom MDR1 (P-gp) lahko pride do prevelike izpostavljenosti aliskirenu (glejte odstavek pod naslovom “Prenašalci” zgoraj in poglavja 4.2, 4.4 in 5.3).
There is a potential for hair growth to occur in areas where GANFORT solution comes repeatedly in contact with the skin surface.
Na mestih, kjer zdravilo GANFORT prihaja v stik s kožo, se lahko pojavi povečana rast dlak.
There is a potential for increased risk of constipation when taking eluxadoline (see section 4.8).
Med zdravljenjem z eluksadolinom se lahko poveča tveganje za zaprtost (glejte poglavje 4.8).
There is a potential for increased risk of pancreatitis, not associated with sphincter of Oddi spasm, when taking eluxadoline (see section 4.8).
Med zdravljenjem z eluksadolinom se lahko zveča tveganje za pankreatitis, ki ni povezan s spazmom Oddijevega sfinktra (glejte poglavje 4.8).
There is a potential for interaction between oral tedizolid phosphate and orally administered substrates of Breast Cancer Resistance Protein (BCRP).
Obstaja možnost interakcij med peroralnim tedizolid fosfatom in peroralnimi substrati proteina odpornosti pri raku dojke (BCRP – breast cancer resistance protein).
There is a potential for reduction or increase in the plasma concentrations of phenytoin, phenobarbital and other anticonvulsants that are substrates of CYP450 isoenzymes when co- administered with efavirenz.
Pri sočasni uporabi z efavirenzem obstaja možnost zmanjšanja ali povečanja plazemskih koncentracij fenitoina, fenobarbitala in drugih antikonvulzivov, ki so substrati za izoencime CYP450.
There is a potential for tedizolid phosphate to inhibit organic anion transporter (OATP1B1) based on in vitro data.
Na podlagi podatkov in vitro obstaja možnost, da bo tedizolid fosfat zaviral organski anionski prenašalec (OATP1B1).
There is a potential risk that [90Y]-radiolabelled Zevalin after pretreatment with rituximab could cause toxic effects on the male and female gonads (see sections 4.4 and 4.6).
Obstaja možno tveganje, da povzroča z [90Y] označeno zdravilo po predhodnem zdravljenju z rituksimabom toksične učinke na moške in ženske spolne žleze (glejte poglavji 4.4 in 4.6).
There is a potential risk that ionizing radiation by [90Y]-radiolabelled Zevalin could cause toxic effects on female and male gonads (see sections ‘4.4 and 5.2).
Obstaja potencialno tveganje, da lahko ionizirajoče sevanje z [90Y] označenega zdravila Zevalin povzroči toksične učinke na ženske in moške spolne žleze (glejte poglavji 4.4 in 5.2).
There is a potential risk that ionizing radiation by [90Y]-radiolabelled Zevalin could cause toxic effects on female and male gonads.
Obstaja potencialno tveganje, da lahko ionizirajoče sevanje z [90Y] označenega zdravila Zevalin povzroči toksične učinke na ženske in moške spolne žleze.
There is a preservative in SIMBRINZA (called benzalkonium chloride) that may cause eye irritation and is known todiscolour soft contact lenses.
Zdravilo SIMBRINZA vsebuje konzervans (imenovan benzalkonijev klorid), ki lahko povzroči draženje očesa in spremeni barvo mehkih kontaktnih leč.
there is a problem with the pump or the pump alarm sounds
je kakšna težava s črpalko, ali se oglasi alarm črpalke.
There is a rare chance that you may experience an anaphylactic reaction (a severe, sudden allergic reaction) to Nuwiq.
Obstaja majhna verjetnost, da priide do anafilaktične reakcije (huda, nenadna alergijska reakcija) na zdravilo Nuwiq.
There is a risk for a significant, but transient loss of visual acuity during the first week after the injection.
V prvem tednu po injiciranju obstaja tveganje za večjo, a prehodno izgubo ostrine vida.
There is a risk for birth defects when ribavirin is given to a female patient that becomes pregnant.
Pri dajanju ribavirina bolnicam, ki zanosijo, obstaja tveganje prirojenih okvar pri novorojenčku.
There is a risk for premature delivery (<37 week) (incidence of 66 of 123 births, i.e.
Obstaja tveganje za prezgoden porod (< 37 tednov) (incidenca 66 od 123 rojstev, tj.
There is a risk for premature delivery (<37 week) (incidence of 66 of 123 births, i.e.
Obstaja tveganje za prezgoden porod (< 37 tednov) (pri 66 od 123 rojstev, tj. pojavnost
There is a risk of anaemia - changes in red blood cells after an operation that may cause fatigue and breathlessness
obstaja tveganje za anemijo - spremembe v rdečih krvničkah po operaciji, ki lahko povzročijo utrujenost in zadihanost
There is a risk of cerebrovascular disease e.g. stroke, or transient ischaemic attack (transient reduced blood flow to the brain)/mini-stroke or angina, or blockages to blood vessels to the heart or brain
obstaja nevarnost možganskožilnih bolezni, npr. možganska kap ali prehodni ishemični napad (prehodno zmanjšan pretok krvi v možgane)/mini možganska kap ali angina ali ovira do krvnih žil, srca ali možganov
There is a risk of feeling drowsy when you are given Olanzapine Apotex.
Obstaja tveganje, da se boste po tem, ko ste dobili zdravilo Olanzapin Apotex, počutili zaspane.
There is a risk of feeling drowsy when you are given OLANZAPINE CIPLA.
Obstaja tveganje, da se boste po tem, ko ste dobili zdravilo OLANZAPIN CIPLA, počutili zaspane.
There is a risk of feeling drowsy when you are given Olanzapine Glenmark Europe.
Obstaja tveganje, da se boste po tem, ko ste dobili zdravilo Olanzapin Glenmark Europe, počutili zaspane.
There is a risk of feeling drowsy when you are given Olanzapine Glenmark.
Obstaja tveganje, da se boste po tem, ko ste dobili zdravilo Olanzapin Glenmark, počutili zaspane.
There is a risk of feeling drowsy when you are given Olanzapine Mylan.
Obstaja tveganje, da se boste po tem, ko ste dobili zdravilo OLANZAPIN MYLAN, počutili zaspane.
There is a risk of feeling drowsy when you are given Olazax.
Obstaja tveganje, da se boste po tem, ko ste dobili zdravilo Olazax, počutili zaspane.
There is a risk of feeling drowsy when you are given Zalasta.
Obstaja tveganje, da se boste potem, ko boste vzeli zdravilo Zalasta, počutili zaspane.
There is a risk of neoplasia due to treatment with GH.
Zdravljenje z rastnim hormonom je povezano s tveganjem za pojav novotvorb.
There is a risk of QTc prolongation and Vibativ should be used with caution in patients taking medicinal products known to prolong the QT interval.
Obstaja tveganje za podaljšanje intervala QTc, zato je treba zdravilo Vibativ uporabljati previdno pri bolnikih, ki jemljejo zdravila, za katera je znano, da podaljšujejo interval QTc.
There is a risk of your hepatitis getting worse (see section 2).
Obastaja tveganje, da se vam hepatitis poslabša (glejte poglavje 2).
There is a risk that pre-exposure prophylaxis may encourage risky behaviour but one of the main studies found that participation in the study reduced risky behaviour.
Obstaja tveganje, da bi predeskpozicijska profilaksa utegnila spodbujati tvegano vedenje, a v eni od glavnih študij so ugotovili, da je bilo zaradi sodelovanja v študiji to manjše.
There is a separate Package Leaflet for Emtriva 10 mg/ml oral solution.
Za uporabo peroralne raztopine Emtriva 10 mg/ml je na voljo posebno navodilo za uporabo.
There is a separate Package Leaflet for Emtriva 200 mg hard capsules.
Za uporabo Emtriva 200 mg trde kapsule je na voljo posebno navodilo za uporabo.
There is a slight risk that higher doses of Nonafact will cause clots to form in blood vessels, resulting in thrombosis.
Obstaja majhno tveganje, da višji odmerki zdravila Nonafact povzročijo tvorbo krvnih strdkov v žilah, kar povzroči trombozo.
There is a small chance that skin cancer could develop with long term use of Voriconazole Hospira.
Pri dolgotrajni uporabi zdravila Vorikonazol Hospira obstaja majhna verjetnost pojava kožnega raka.
There is a small chance that you may experience an anaphylactic reaction (a severe, sudden allergic reaction) to ALPROLIX.
Obstaja majhna možnost, da boste doživeli anafilaktično reakcijo (huda, nenadna alergijska reakcija) na zdravilo ALPROLIX.
There is a small chance that you may experience an anaphylactic reaction (a severe, sudden allergic reaction) to ELOCTA.
Obstaja majhna možnost, da boste doživeli anafilaktično reakcijo (huda, nenadna alergijska reakcija) na zdravilo ELOCTA.
There is a small spike inside the top of the cap - in the centre.
V notranjosti vrha zaporke je majhna konica – v sredini.
There is a10-fold selectivity over PDE6 which is involved in the phototransduction pathway in the retina.
Za PDE5 je 10-krat bolj selektiven kot za PDE6, ki je vključena v fototransdukcijsko pot v mrežnici.
There is also a risk of a disorder reducing the amount of oxygen in the blood (methaemoglobinaemia).
zvenenje v ušesih; obstaja tudi tveganje za motnjo zmanjšanja količine kisika v krvi (methemoglobinemijo).
There is also a risk of spontaneous abortion, premature birth and low birth weight babies in pregnant women taking mercaptopurine.
Obstaja tudi tveganje spontanega splava ter prezgodnjega rojstva in nizke porodne teže otrok, ki so se rodili ženskam, ki so v nosečnosti jemale merkaptopurin.
There is also an increased risk of liver problems and thromboembolic complications (problems with clots in blood vessels) in patients with thrombocytopenia and advanced chronic hepatitis C who are treated with a medicine called interferon and Revolade.
Pojavlja se tudi povečano tveganje za težave z jetri in trombembolične zaplete (težave s strdki v žilah) pri bolnikih s trombocitopenijo in napredovalim kroničnim hepatitisom C, ki so zdravljeni z zdravilom, imenovanim interferon, in zdravilom Revolade.
There is also no experience of treatment with Lucentis in diabetic patients with an HbA1c over 12% and uncontrolled hypertension.
Prav tako ni nobenih izkušenj z uporabo zdravila Lucentis pri sladkornih bolnikih z vrednostjo HbA1c nad 12 % in z neurejeno hipertenzijo.
There is also no information on the re-use of Celsentri in patients who have taken it in the past, but in whom it stopped working.
Prav tako ni podatkov o učinkovitosti zdravila Celsentri pri ponovni uporabi pri bolnikih, ki so ga v preteklosti že jemali, a je prenehalo učinkovati.
There is also no information on using Atripla with other anti-HIV medicines.
Prav tako ni podatkov o sočasnem jemanju zdravila Atripla z drugimi zdravili proti virusu HIV.
There is an association between plasma BLyS levels and SLE disease activity.
Koncentracija BLyS v plazmi in aktivnost SLE sta povezani.
There is an increased background risk for lymphoma and leukemia in rheumatoid arthritis patients with long-standing highly active, inflammatory disease, which complicates the risk estimation.
Pri bolnikih z revmatoidnim artritisom z dolgotrajno, zelo aktivno vnetno boleznijo je zvečano osnovno tveganje za limfome in levkemijo, kar komplicira oceno tveganja.
There is an increased background risk for lymphoma and leukemia in rheumatoid arthritis patients with long-standing highly active, inflammatory disease, which complicatesthe risk estimation.
Pri bolnikih z revmatoidnim artritisom z dolgotrajno, zelo aktivno vnetno boleznijo je zvečano osnovno tveganje za limfome in levkemijo, kar komplicira oceno tveganja.
There is an increased background risk for lymphoma and leukemia in rheumatoid arthritis patients with long-standing, highly active, inflammatory disease, which complicates the risk estimation.
Pri bolnikih z revmatoidnim artritisom z dolgotrajno, zelo aktivno vnetno boleznijo je zvečano osnovno tveganje za limfome in levkemijo, kar komplicira oceno tveganja.
There is an increased chance of having twins or even more than two babies, even when only one embryo is transferred into theuterus.
Tudi v primeru, ko je bil v maternico prenesen le en zarodek, je večja verjetnost, da bo ženska rodila dvojčka ali celo več otrok.
There is an increased risk for adverse reactions, including potentially fatal hepatic decompensation and thromboembolic events, in thrombocytopenic HCV patients with advanced chronic liver disease, as defined by low albumin levels ≤ 35 g/L or model for end stage liver disease (MELD) score ≥ 10, when treated with eltrombopag in combination with interferon-based therapy.
Pri sočasnem zdravljenju z interferonom in eltrombopagom pri trombocitopeničnih bolnikih s HCV in z napredovalo kronično boleznijo jeter, ki je definirana z nizko vrednostjo albuminov ≤ 35 g/L ali oceno po prognostičnem modelu napredovale jetrne bolezni (MELD - model for end stage liver disease) ≥ 10, obstaja večje tveganje za neželene učinke, vključno z možno jetrno dekompenzacijo s smrtnim izidom in trombemboličnimi dogodki.
There is an increased risk of lactic acidosis following excessive alcohol consumption (particularly in the case of fasting, malnutrition, or liver disease) due to the active substance metformin.
Zaradi zdravilne učinkovine metformina je po pitju prevelike količine alkohola (zlasti pri postu, pomanjkljivem prehranjevanju ali jetrni bolezni) povečano tveganje pojava laktacidoze.
There is an increased risk of photosensitivity (sensitivity to light)
Obstaja velika nevarnost nastanka fotosenzitivnih reakcij (preobčutljivosti na svetlobo).
There is an increased risk of photosensitivity (sensitivity to light)
obstaja velika nevarnost, da se razvije preobčutljivost na svetlobo.
There is an increased risk of severe hypotension and renal insufficiency when patients with bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney are treated with angiotensin converting enzyme inhibitors or angiotensin II receptor antagonists.
Pri bolnikih z obojestransko zožitvijo ledvičnih arterij ali zožitvijo arterije delujoče ledvice se med jemanjem zaviralcev angiotenzinske konvertaze ali antagonistov angiotenzina II poveča nevarnost pojava hude hipotenzije in motnje v ledvičnem delovanju.
There is an increased risk of severe hypotension and renal insufficiency when patients with bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney are treated with angiotensin converting enzyme inhibitors or angiotensin-II receptor antagonists.
Pri bolnikih z obojestransko zožitvijo ledvičnih arterij ali zožitvijo arterije delujoče ledvice se med jemanjem zaviralcev angiotenzinske konvertaze ali antagonistov angiotenzina II zveča nevarnost pojava hude hipotenzije in motnje v ledvičnem delovanju.
There is an increased risk of severe hypotension and renal insufficiency when patients with bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney are treated with medicinal products that affect the renin-angiotensin-aldosterone system.
Bolnike z bilateralno stenozo ledvične arterije ali stenozo arterije edine delujoče ledvice, ki dobivajo zdravila z vplivom na sistem renin-angiotenzin-aldosteron, bolj ogrožata huda hipotenzija in zmanjšano delovanje ledvic.
There is an increased risk of severe hypotension and renal insufficiency when patients with bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney are treated with medicinal products that affect the renin-angiotensin-aldosterone system.
Pri bolnikih z obojestransko stenozo ledvične arterije ali s stenozo arterije ene same delujoče ledvice, je pri uporabi zdravil z vplivom na sistem renin-angiotenzin-aldosteron, povečano tveganje za hudo hipotenzijo in ledvično insuficienco.
There is an ongoing imposed post-authorisation study to better characterize the safety profile of the contraceptive combination nomegestrol/estradiol.
V teku je študija po pridobitvi dovoljenja za promet, ki je bila zahtevana za podrobnejšo opredelitev varnostnega profila kombiniranega kontraceptiva nomegestrola/estradiola.
There is any suspicion that the partially used vial has been contaminated.
Sumite, da je bila delno uporabljena viala kontaminirana.
There is any suspicion that the partially used vial has been contaminated.
Sumite, da je delno uporabljena viala kontaminirana.
There is at present insufficient data to exclude the possibility of folate deficiency during long term Renvela treatment.
Trenutno ni dovolj podatkov, da bi izključili možnost pomanjkanja folatov med dolgotrajnim zdravljenjem z zdravilom Renvela.
There is at present insufficient data to exclude the possibility of folate deficiency during long term Sevelamer carbonate Zentiva treatment.
Trenutno ni dovolj podatkov, da bi izključili možnost pomanjkanja folatov med dolgotrajnim zdravljenjem z zdravilom Sevelamer carbonate Zentiva.
There is clinical evidence of an association between IVIg administration and thromboembolic events such as myocardial infarction, cerebral vascular accident (including stroke), pulmonary embolism and deep vein thrombosis which is assumed to be related to a relative increase in blood viscosity through the high influx of immunoglobulin in at-risk patients.
Obstajajo klinični dokazi za povezavo med uporabo i.v. imunoglobulinov in tromboemboličnimi dogodki, kot so miokardni infarkt, cerebrovaskularni inzult (vključno z možgansko kapjo), pljučna embolija in globoka venska tromboza, ki naj bi bili povezani z relativnim povečanjem viskoznosti krvi zaradi dovajanja velike količine imunoglobulinov pri bolnikih z dejavniki tveganja.
There is cross resistance with other macrolides.
Obstaja navzkrižna rezistenca z drugimi makrolidi.
There is cross resistance with other macrolides.
Obstoja navzkrižna rezistenca z drugimi makrolidi.
There is currently no experience of repeat administrations in posterior segment non-infectious uveitis or beyond 2 implants in Retinal Vein Occlusion.
Trenutno ni izkušenj z večkratnim odmerjanjem pri nenalezljivem posteriornem uveitisu ali z odmerjanjem več kot 2 vsadkov pri okluziji retinalne vene.
There is currently no known antidote to reverse the effects of ticagrelor, and ticagrelor is not expected to be dialysable (see section 4.4).
Trenutno ni antidota, ki bi odpravil učinke ticagrelorja in zdravilna učinkovina se z dializo ne odstrani (glejte poglavje 4.4).
There is data showing that the second injection can be given up to 11 months after the first one.
Nekateri podatki kažejo, da se lahko drugo injiciranje opravi največ 11 mesecev po prvem.
There is data that a second injection given up to 11 months after the first dose results in high seroconversion rates (see section 5.1).
Po nekaterih podatkih povzroči drugi odmerek cepiva, če ga oseba prejme najkasneje 11 mesecev po prvem odmerku, visoke odstotke serkonverzije (glejte poglavje 5.1).
There is evidence suggesting that all Grade (US National Cancer Institute- Common Terminology Criteria for Adverse Events [NCI-CTCAE v.3]) proteinuria may be related to the dose.
Obstajajo dokazi, da je proteinurija vseh stopenj (US National Cancer Institute - Common Terminology Criteria for Adverse Events [NCI-CTCAE v.3]) lahko povezana z odmerkom.
There is evidence that the concentration of macrolides is higher at the site of infection than in plasma, in particular in neutrophils, alveolar macrophages and alveolar epithelial cells.
Obstajajo dokazi, da je koncentracija makrolidov na mestu infekcije višja kot v plazmi, zlasti v neutrofilih, alveolarnih makrofagih in alveolarnih epitelijskihcelicah.
There is evidence that the concentration of macrolides is higher at the site of infection than in plasma, in particular in neutrophils, alveolar macrophages and alveolar epithelial cells.
Ugotovili so, da je koncentracija makrolidov višja na mestu infekcije kot v plazmi, zlasti visoka je v nevtrofilcih, alveolarnih makrofagih in v alveolarnih epitelijskih celicah.